18.7 C
New York
Saturday, June 3, 2023

The Question Is Whether To Buy Or Not To Buy Pacira BioSciences Inc. (NASDAQ: PCRX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Pacira BioSciences Inc. (PCRX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $46.45. The Pacira BioSciences Inc. has recorded 79,973 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

Pacira BioSciences Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $46.45 and fluctuated between $47.00 as its day high and $45.45 as its day low. The current market capitalization of Pacira BioSciences Inc. is $2.11B. A total of 1.0 million shares were traded on the day, compared to an average of 562.06K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, PCRX has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 7,000 and the disposition of 7,000 shares. Over the last 12 months, there were 23 BUYs and 40 SELLs from insiders. Insiders purchased 141,020 shares during that period but sold 90,106.

In the most recent transaction, Brege Laura sold 7,000 shares of PCRX for 40.72 per share on Apr 03. After the transaction, the Director now owns 10,147 company shares. In a previous transaction on Jan 05, MOLLOY ANTHONY sold 546 shares at 38.31 per share. PCRX shares that Chief Lgl & Compliance Officer owns now total 19,450.

Among the insiders who sold shares, MOLLOY ANTHONY disposed of 158 shares on Jan 04 at a per-share price of $39.09. This resulted in the Chief Lgl & Compliance Officer holding 19,996 shares of PCRX after the transaction. In another insider transaction, REINHARDT MAX sold 1,380 shares at $58.00 per share on Oct 07. Company shares held by the President, Rest of World now total 31,378.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for PCRX in the last 3 months, the mean price target is $63.56 with high estimates of $80.00 and low estimates of $50.00. In terms of 52-week highs and lows, PCRX has a high of $75.16 and a low of $35.35.

As of this writing, PCRX has an earnings estimate of $0.62 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of $0.69 per share and a lower estimate of $0.56. The company reported an EPS of $0.64 in the last quarter, which was -15.80% lower than expectations of $0.76.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PCRX’s latest balance sheet shows that the firm has $656.41M in Cash & Short Term Investments as of fiscal 2021. There were $1.13B in debt and $521.12M in liabilities at the time. Its Book Value Per Share was $16.89, while its Total Shareholder’s Equity was $730.41M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Overweight with a score of 4.40. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles